FDA Calls for Testing Before Treatment With Widely Used Chemotherapies

(MedPage Today) — Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) deficiency and should test for DPYD variants before starting treatment with capecitabine (Xeloda) and…

Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/119774

Author :

Publish date : 2026-02-06 17:59:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

FDA Calls for Testing Before Treatment With Widely Used Chemotherapies

Rural America Needs Immigrant Doctors More Than Ever

FDA Updates Risks in Capecitabine, Fluorouracil Labels

Related Posts

Do Women Actually Want At-Home Cervical Cancer Screening?

3D-Printed Breast Tissue; Cancer and Ultraprocessed Food; Agent Orange and Melanoma

Neuroprotective Agent Improved Outcomes After Acute Ischemic Stroke

Thrombolysis Window May Extend to 24 Hours for Non-LVO Strokes

Gabapentin Misuse Persists, Two Analyses Show

As ICE Uses Medicaid Data, Hospitals Are in a Bind Over Warning Immigrant Patients

Do Women Actually Want At-Home Cervical Cancer Screening?

3D-Printed Breast Tissue; Cancer and Ultraprocessed Food; Agent Orange and Melanoma

Neuroprotective Agent Improved Outcomes After Acute Ischemic Stroke

Thrombolysis Window May Extend to 24 Hours for Non-LVO Strokes

Gabapentin Misuse Persists, Two Analyses Show

As ICE Uses Medicaid Data, Hospitals Are in a Bind Over Warning Immigrant Patients

FDA Updates Risks in Capecitabine, Fluorouracil Labels

FDA Calls for Testing Before Treatment With Widely Used Chemotherapies

Categories

Archives